STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Vaccines Review Article

Advancing Cancer Vaccine Development through CRISPR/Cas9 Technologies and Future Opportunities

  1. Mohammad Nadeem Khan Department of Pharmacology (Clinical Pharmacology), SAMC&PGI, Sri Aurobindo University

Abstract

The advent of CRISPR/Cas9 genome editing has revolutionized the cancer immunotherapy market, offering unprecedented precision and versatility in the development of next-generation cancer vaccines. This review examines how CRISPR technologies are being integrated into various stages of cancer vaccine development including neoantigen discovery, dendritic cell engineering, cancer cell reprogramming, and tumor microenvironment modulation. In the area of neoantigen discovery, CRISPR enables rapid identification and validation of tumor-specific mutations, thereby supporting the design of highly personalized vaccines. Engineered dendritic cells, generated through CRISPR-based modifications, demonstrate improved antigen presentation and enhanced activation of T-cell responses. Similarly, reprogramming of cancer cells using targeted gene editing facilitates the development of whole-cell vaccines with increased immunogenicity. Beyond individual cell manipulation, CRISPR also provides opportunities to reshape the tumor microenvironment by knocking out immunosuppressive pathways or introducing immune-stimulatory factors, thereby improving vaccine potency. Newer CRISPR systems, including Cas12 and Cas13, along with advanced strategies such as CRISPRa/i and multiplex gene editing, broaden the scope of cancer vaccine design, offering refined control over gene expression and multi-targeted approaches. The choice of delivery platforms including lipid nanoparticles, viral vectors, electroporation, and exosome-based carriers further influences clinical applicability. Importantly, several ongoing clinical trials are already testing CRISPR- based cancer immunotherapies, underscoring the translational potential of these technologies. Despite promising results, challenges remain, including off-target effects, immunogenicity, ethical issues, and regulatory barriers. Finally, we present future directions, including CRISPR- guided nanotumors and AI-driven neoantigen prioritization, which together highlight the importance of CRISPR.

Keywords

References (136)

  1. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic
  2. cancer vaccines. The Journal of Clinical Investigation. 2015 Sep 1;125(9):3401-
  3. Burns KH. Transposable elements in cancer. Nature Reviews Cancer. 2017
  4. Jul;17(7):415-24.
  5. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A
  6. programmable dual-RNA–guided DNA endonuclease in adaptive bacterial
  7. immunity. Science. 2012 Aug 17;337(6096):816-21.
  8. doi:10.1126/science.1225829
  9. Doudna JA, Charpentier E. The new frontier of genome engineering with
  10. CRISPR-Cas9. Science. 2014;346(6213):1258096. doi:10.1126/science.1258096
  11. Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, et al. In
  12. vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
  13. Nature. 2017;547(7664):413–8. doi:10.1038/nature23270
  14. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy:
  15. understanding the characteristics of tumor-infiltrating immune cells and their
  16. therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.
  17. doi:10.1038/s41423-020-0488-6
  18. Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al.
  19. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human
  20. chimeric antigen receptor T cells. Sci Rep. 2017;7:737. doi:10.1038/s41598-017-
  21. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-
  22. editing system for therapeutic applications. J Control Release. 2022;341:1–15.
  23. doi:10.1016/j.jconrel.2021.11.034
  24. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al.
  25. Search-and-replace genome editing without double-strand breaks or donor DNA.
  26. Nature. 2019;576(7785):149–57. doi:10.1038/s41586-019-1711-4
  27. Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and
  28. consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52–64.
  29. doi:10.1016/j.tcb.2015.07.009
  30. Su S, Zou Z, Chen F, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on
  31. human primary T cells from cancer patients. Sci Rep. 2016;6:20070.
  32. doi:10.1038/srep20070
  33. Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type
  34. chemokines shapes tumour immunity and immunotherapy. Nature.
  35. 2015;527(7577):249–53. doi:10.1038/nature15520
  36. Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway’ of human cancer
  37. immunotherapy: targeting random somatic mutations. Nat Immunol.
  38. 2017;18(3):255–62. doi:10.1038/ni.3682
  39. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-
  40. mediated gene knockout in primary T cells. J Exp Med. 2018;215(3):985–97.
  41. doi:10.1084/jem.20171626
  42. Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided
  43. regulation of transcription in eukaryotes. Cell. 2013;154(2):442–51.
  44. doi:10.1016/j.cell.2013.06.044
  45. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided
  46. endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759–71.
  47. doi:10.1016/j.cell.2015.09.038
  48. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al.
  49. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to
  50. checkpoint inhibition. Cell. 2021;184(3):596–614.e14.
  51. doi:10.1016/j.cell.2020.12.032
  52. Yuan Y, Wang H, Wang Y, Huang L, Wu X, Zhou Y, et al. CRISPR-Cas9 screen
  53. identifies PTPN2 as a key regulator of antigen presentation and tumor immunity
  54. in lung cancer. J Exp Med. 2023;220(2):e20221135. doi:10.1084/jem.20221135
  55. Liu Q, Cheng K, Liao Y, Chen Y, Zhao M, Lu Y, et al. DeepHLApan and
  56. personalized neoantigen discovery using CRISPR-based tumor models. Brief
  57. Bioinform. 2024;25(1):bbae039. doi:10.1093/bib/bbae039
  58. Rodrigues PF, Alberti-Servera L, Eremin A, Grajales-Reyes GE, Ivanek R,
  59. Tussiwand R. Distinct progenitor lineages contribute to the heterogeneity of
  60. plasmacytoid dendritic cells. Nat Immunol. 2021;22(5):620–35.
  61. doi:10.1038/s41590-021-00901-0
  62. Joosse ME, Topham DJ. The role of dendritic cells in shaping adaptive immunity
  63. and tolerogenic responses. Front Immunol. 2022;13:833982.
  64. doi:10.3389/fimmu.2022.833982
  65. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a
  66. target base in genomic DNA without double-stranded DNA cleavage. Nature.
  67. 2016;533(7603):420–24. doi:10.1038/nature17946
  68. Gao Y, Zhang C, Zhou Y, Shen Y, Du Y, Wu Y, et al. Tumor cell-intrinsic PD-L1
  69. promotes tumor-initiating cell generation and functions in melanoma and breast
  70. cancer. Cell Rep. 2022;38(2):110249. doi:10.1016/j.celrep.2022.110249
  71. Chen Y, Zhang Y, Zhang Y, Wang Y, Ding M, Li L, et al. Engineering tumor
  72. cell-based vaccines with CRISPR-mediated cytokine release for enhanced
  73. immunogenicity. Adv Sci (Weinh). 2023;10(12):2207024.
  74. doi:10.1002/advs.202207024
  75. Wang H, Mooney DJ. Biomaterial-assisted targeted modulation of immune cells
  76. in cancer immunotherapy. Nat Mater. 2023;22(4):491–503. doi:10.1038/s41563-
  77. Zhang Y, Chen J, Zhou F, Zhang C, Wang X, Zhang Y, et al. CRISPR-mediated
  78. knockdown of VEGFA and IL-6 enhances antitumor immunity by remodeling the
  79. tumor microenvironment. Cancer Res. 2022;82(10):1854–66. doi:10.1158/0008-
  80. 5472.CAN-21-3966
  81. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer
  82. progression and therapeutic resistance. Tumour Biol.
  83. 2021;43(1):10104283211041229. doi:10.1177/10104283211041229
  84. Deng L, Ren J, Liu L, Liu Q, Wang D, Zhang Y, et al. Dual CRISPR-mediated
  85. knockout of PD-L1 and activation of STING enhances immunogenicity of cold
  86. tumors. Nat Commun. 2024;15:4711. doi:10.1038/s41467-024-34711-9
  87. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor
  88. interferon signaling regulates a multigenic resistance program to immune
  89. checkpoint blockade. Cell. 2016;167(6):1540–54.e12.
  90. doi:10.1016/j.cell.2016.11.022
  91. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, et
  92. al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9
  93. complex. Nature. 2015;517(7536):583–88. doi:10.1038/nature14136
  94. Bowling S, Sritharan D, Osorio FG, Nguyen M, Cheung P, Rodriguez-Fraticelli
  95. AE, et al. An engineered CRISPR-Cas9 mouse line for simultaneous readout of
  96. lineage histories and gene expression profiles in single cells. Cell.
  97. 2020;181(2):325–40.e24. doi:10.1016/j.cell.2020.02.043
  98. Han X, Liu Z, Jo MC, Zhang K, Li Y, Zeng Z, et al. CRISPR-Cas9 delivery
  99. mediated with synthetic hybrid lipid nanoparticles for cancer immunotherapy.
  100. Adv Mater. 2019;31(52):e1902952. doi:10.1002/adma.201902952
  101. Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH. Transposon-encoded
  102. CRISPR–Cas systems direct RNA-guided DNA integration. Nature.
  103. 2019;571(7764):219–25. doi:10.1038/s41586-019-1323-z
  104. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in
  105. vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
  106. doi:10.1038/nrd.2017.243
  107. Zhao X, Yang K, Zhao R, Ji T, Wang X, Yang X, et al. Inducing enhanced
  108. immunogenic tumor cell death with nanocarrier-mediated codelivery of epigenetic
  109. drugs and TLR agonists. Biomaterials. 2020;232:119681.
  110. doi:10.1016/j.biomaterials.2019.119681
  111. Wang H, Zhang X, Zuo Y, Wang J, Li L, Yu T, et al. Co-delivery of mRNA
  112. vaccine and CRISPR/Cas9 system using lipid nanoparticles for cancer
  113. immunotherapy. Biomaterials. 2023;295:121999.
  114. doi:10.1016/j.biomaterials.2022.121999
  115. Li C, Liu H, Sun Y, Wang J, Yang J, Zheng S, et al. A CRISPR-based STING
  116. pathway booster enhances mRNA vaccine-induced immunity against cold tumors.
  117. Nat Biomed Eng. 2024;8(1):112–25. doi:10.1038/s41551-023-01131-2
  118. Abbasi J. Programmable mRNA translation for future vaccines. JAMA.
  119. 2023;329(22):1892. doi:10.1001/jama.2023.6963
  120. Liu X, Tang X, Li H, Li R, Fan H, Lu J, et al. Artificial intelligence-augmented
  121. CRISPR design streamlines personalized neoantigen vaccine development. Nat
  122. Commun. 2023;14(1):2921. doi:10.1038/s41467-023-38685-3
  123. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat
  124. Rev Mater. 2021;6(12):1078–94. doi:10.1038/s41578-021-00358-0
  125. Kulkarni JA, et al. The current landscape of nucleic acid delivery via lipid
  126. nanoparticles. Nat Nanotechnol. 2021;16(6):630–43.
  127. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene
  128. therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–75.
  129. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia.
  130. 2018;32(7):1529–46.
  131. Stadtmauer EA, et al. CRISPR-engineered T cells in patients with refractory
  132. cancer. Science. 2020;367(6481):eaba7365.
  133. Wang P, et al. Gold nanoparticle-based gene therapy: recent advances and future
  134. prospects. ACS Appl Bio Mater. 2018;1(4):561–75.
  135. Kamerkar S, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS
  136. in pancreatic cancer. Nature. 2017;546(7659):498–503.